인플루엔자 진단 검사 시장 : 검사 유형별, 최종 용도별 및 예측(2023-2032년)

Influenza Diagnostic Tests Market is estimated to witness 6.3% CAGR between 2023 and 2032, owing to the recurrent global outbreaks of influenza that highlight the critical need for accurate and rapid diagnostic solutions. As per WHO October 2023 report, there were approximately a billion cases of seasonal influenza annually, which included 3-5 million cases of severe illness. As the world grapples with the ongoing threat of influenza, diagnostic tests help in early detection, effective treatment, and containment of the virus.

The continual evolution of diagnostic tools, including molecular assays, rapid antigen tests, and nucleic acid amplification techniques, enhances the precision and efficiency of influenza diagnosis. The quest for more sensitive, specific, and quicker diagnostic methods encourages R&D investments.

Influenza diagnostic tests industry is segmented on the basis of test type, end-use, and region.

Molecular diagnostic assays segment is poised for substantial growth over the forecast period, as polymerase chain reaction (PCR) and nucleic acid amplification tests, offer high sensitivity and specificity in detecting influenza viruses. This precision is important for accurate and timely diagnosis, allowing for prompt initiation of appropriate treatments and containment measures. The growing demand for rapid and reliable diagnostic solutions, coupled with advancements in molecular diagnostic technologies, contribute to the segment growth.

Research laboratories segment will generate notable revenues for the market during 2023-2032, owing to the instrumental role in advancing diagnostic technologies and methodologies. Research laboratories help in the development of innovative diagnostic assays and the continual improvement of existing testing platforms. The pursuit of excellence in diagnostic accuracy within research laboratories directly translates into the availability of more reliable and efficient tests, elevating the overall standard of diagnostic capabilities.

Asia Pacific influenza diagnostic tests industry is slated to witness a significant growth rate through 2032, attributed to rapid urbanization, increased healthcare awareness, and proactive government initiatives to combat infectious disease. The increasing incidence of influenza, coupled with a rising awareness of the economic impact of infectious diseases, fuels the demand for precise diagnostic solutions. Moreover, strategic collaborations between healthcare institutions, governments, and diagnostic companies contribute to a more efficient response to influenza outbreaks, favoring the regional market outlook.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Base estimates & working
  • 1.2.1 Data collection
• 1.3 Forecast parameters
• 1.4 COVID-19 impact at global level
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Influenza diagnostic tests industry 360 degree synopsis, 2018 - 2032
• 2.2 Business trends
• 2.3 Regional trends
• 2.4 Test type trend
• 2.5 End-use trends

Chapter 3 Influenza Diagnostic Tests Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing prevalence of influenza
    • 3.2.1.2 Rise in demand for rapid diagnostic tests
    • 3.2.1.3 Technological advancements
    • 3.2.1.4 Increase in R&D activities
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Variabilities in test sensitivity and specificity
    • 3.2.2.2 Stringent regulatory guidelines
• 3.3 Growth potential analysis
  • 3.3.1 By test type
  • 3.3.2 By end-use
• 3.4 COVID-19 impact analysis
• 3.5 Regulatory landscape
• 3.6 Reimbursement scenario
• 3.7 Technology landscape
• 3.8 GAP analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

• 4.1 Introduction
• 4.2 Company matrix analysis, 2022
• 4.3 Company market share analysis, 2022
• 4.4 Competitive positioning matrix
• 4.5 Vendor matrix analysis
• 4.6 Strategy dashboard, 2022

Chapter 5 Influenza Diagnostic Tests Market Size and Forecast, By Test Type (USD Million)

• 5.1 Key test type trends
• 5.2 Traditional diagnostic test
  • 5.2.1 Rapid influenza diagnostic test (RIDT)
  • 5.2.2 Direct fluorescent antibody test (DFAT)
  • 5.2.3 Viral culture
  • 5.2.4 Serological assay
• 5.3 Molecular diagnostic assay
  • 5.3.1 RT-PCR
  • 5.3.2 Loop-mediated isothermal amplification-based Assay (LAMP)
  • 5.3.3 Nucleic acid sequence-based amplification test (NASBAT)
  • 5.3.4 Simple amplification-based assay (SAMBA)
  • 5.3.5 Other molecular diagnostic assays

Chapter 6 Influenza Diagnostic Tests Market Size and Forecast, By End-use (USD Million)

• 6.1 Key end-use trends
• 6.2 Hospitals
• 6.3 Diagnostics centers
• 6.4 Research laboratories
• 6.5 Other end-users

Chapter 7 Influenza Diagnostic Tests Market Size and Forecast, By Region (USD Million)

• 7.1 Key regional trends
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 France
  • 7.3.4 Spain
  • 7.3.5 Italy
  • 7.3.6 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Australia
  • 7.4.5 South Korea
  • 7.4.6 Rest of Asia Pacific
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Mexico
  • 7.5.3 Argentina
  • 7.5.4 Rest of Latin America
• 7.6 Middle East & Africa
  • 7.6.1 South Africa
  • 7.6.2 Saudi Arabia
  • 7.6.3 UAE
  • 7.6.4 Rest of MEA

Chapter 8 Company Profiles

• 8.1 F. Hoffmann-La Roche Ltd
• 8.2 Abbott
• 8.3 Becton, Dickinson and Company
• 8.4 Coris BioConcept
• 8.5 DiaSorin SpA
• 8.6 Meridian Bioscience Inc.
• 8.7 Quidel Corporation
• 8.8 Sekisui Diagnostics
• 8.9 Thermo Fischer Scientific Inc.
• 8.10 Hologic Inc.